Drug Database
SC

SCIT Wasp

✓ Approved

HAL Allergy Group · therapeutic agent

What is SCIT Wasp?

SCIT Wasp is a therapeutic agent developed by HAL Allergy Group. It is approved for therapeutic indications via injectable (others) or subcutaneous injection.

Drug Profile

CompanyHAL Allergy Group
RouteInjectable (Others), Subcutaneous Injection
StatusApproved
Sources: ClinicalTrials.gov, HAL Allergy Group

Therapeutic Indications

SCIT Wasp is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Immune system disordersAllergy to animal✓ Approved

Related Research Articles

PubMedFrontiers in immunology2026-09-18

Efficacy of house dust mite allergen immunotherapy in allergic rhinitis: a network meta-analysis based on component-resolved classification.

Guo Shuo S, Wang Kun K, Shi Yawen Y, Hong Fei F et al.

House dust mite allergen immunotherapy (HDM-AIT) trials in allergic rhinitis show substantial efficacy heterogeneity, traditionally evaluated by administration route. Whether clinical efficacy differs among HDM-AIT preparations with different allergen compositional breadth remains unclear. To compare HDM-AIT efficacy using a component-resolved framework that stratifies preparations by allergen compositional breadth. We searched PubMed, Embase, and CENTRAL for double-blind, placebo-controlled randomized trials of HDM-AIT lasting at least 12 months. Interventions were classified as comprehensive-component subcutaneous immunotherapy (CC-SCIT), major-component-dominant subcutaneous immunotherapy (MCD-SCIT), or major-component-dominant sublingual immunotherapy tablet (MCD-SLIT-tablet) using a prespecified component-resolved framework in which the breadth of treatment-induced component-specific IgG4 responses served as the primary node-defining criterion, with component-specific IgG and proteomic evidence used as supportive evidence. Frequentist pairwise and Bayesian network meta-analyses were performed. The primary outcome was symptom score; secondary outcomes were medication score and combined symptom and medication score. Sixteen trials involving 7,329 participants were included. For symptom score, CC-SCIT showed the most favorable estimated treatment effect versus placebo (standardized mean difference [SMD], -0.40; 95% credible interval [CrI], -0.73 to -0.11; surface under the cumulative ranking curve [SUCRA], 82.6%), while MCD-SLIT-tablet showed a more precise estimate supported by a larger evidence base (SMD, -0.30; 95% CrI, -0.41 to -0.20; SUCRA, 60.7%). For medication score, CC-SCIT (SMD, -0.40; 95% CrI, -0.81 to 0.00; SUCRA, 79.8%) and MCD-SCIT (SMD, -0.38; 95% CrI, -0.72 to -0.05; SUCRA, 78.5%) showed similar estimated effects, whereas MCD-SLIT-tablet showed a smaller but more precise effect (SMD, -0.15; 95% CrI, -0.28 to 0.00; SUCRA, 39.9%). For combined symptom and medication score, CC-SCIT showed the largest estimated effect versus placebo (SMD, -0.84; 95% CrI, -1.53 to -0.37; SUCRA, 99.5%). The network was star-shaped, and comparisons among non-placebo treatment nodes were indirect. Posterior rank distributions also indicated uncertainty in the relative ordering of the treatment nodes, particularly those supported by fewer trials. Reported immunologic and compositional profiles of HDM-AIT preparations were associated with variability in trial-level efficacy estimates. These findings support product-level molecular characterization and direct comparative studies as priorities for future precision AIT. https://www.crd.york.ac.uk/PROSPERO/view/, CRD420261307571.

PMID 42755948
Read full article →
PubMedThe World Allergy Organization journal2026-09-18

CRD-guided step-up care for pediatric dust mite allergy: A systematic review of evidence gaps and global disparities (2014-2025).

Yang Wei W, Wang Peiqin P, Wan Zhi Z, Meng Lingjuan L et al.

The management of house dust mite (HDM) allergies in children is evolving with new evidence for precision diagnosis and therapies. However, global disparities in resource availability and regional variations in sensitization profiles challenge the implementation of optimal care. To synthesize the latest evidence (2014-2025) and propose a component-resolved diagnosis (CRD)-guided stepped-care framework for pediatric HDM allergies, addressing evidence gaps and global health disparities. We conducted a systematic review following PRISMA guidelines and searched the PubMed, EMBASE, Cochrane Library, and Web of Science databases for randomized controlled trials, meta-analyses, cohort studies, and clinical guidelines. Two reviewers independently screened records, assessed eligibility, and extracted data. Of 3371 records identified, 92 studies met the inclusion criteria and were included in the qualitative synthesis. The outcomes included the efficacy and safety of environmental controls, immunotherapy (sublingual [SLIT] vs subcutaneous [SCIT]), biologics, and the role of CRD. A narrative synthesis was performed because of substantial clinical heterogeneity across studies, supplemented by recent meta-analyses in a quantitative context. Individual studies reported short-term Der p 1 reductions of 45-60% with physical interventions; however, a meta-analysis of 17 Randomized Clinical Trials (RCTs) revealed that these reductions were insufficient to improve clinical outcomes, and long-term adherence remained poor (<42%). Compared with SCIT, SLIT demonstrated a superior safety profile (local reactions <10%) and lower systemic reaction risk (OR 2.6, 95% CI 1.8-3.8), whereas SCIT was more effective in polysensitized children (symptom remission: 40% vs. 25%; RR 1.60, 95% CI 1.12-2.28). Omalizumab improved lung function (FEV1: +12.5%, p < 0.01) in patients with severe asthma, but its high cost (∼$30,000/year) limited patient access. CRD identified Der p 23 as a key biomarker for asthma severity (OR 2.5, 95% CI 1.3-4.8) and revealed distinct geographic sensitization patterns-such as Der p 1 predominance in Asia versus Der p 23 in Europe. These observations raise the hypothesis that regionally tailored immunotherapy formulations could improve outcomes, although this hypothesis requires prospective validation through multinational clinical trials. Based on the synthesized evidence, this review outlines a preliminary CRD-guided, stepped-care framework that integrates molecular sensitization profiles with clinical phenotype and resource availability. This conceptual model seeks to move beyond conventional one-size-fits-all approaches by proposing resource-stratified pathways that prioritize cost-effective strategies in resource-limited settings while reserving intensive therapies for high-risk subgroups. However, the framework remains conceptual and requires prospective validation in diverse clinical and socioeconomic settings before its utility for addressing global health disparities can be assessed. Future priorities include gathering long-term biologic safety data, conducting real-world cost-effectiveness analyses, and developing globally harmonized, resource-sensitive guidelines.

PMID 42756976
Read full article →
PubMedAnnals of the Entomological Society of America2026-09-13

From two putative inquilines to one definitive parasitoid: clarifying feeding ecology and species limits in Nearctic Euceroptres Ashmead, 1896 wasps (Hymenoptera: Figitidae).

Brown Guerin E GE, Nastasi Louis F LF, Davis Charles C, Sierra Nicolas N et al.

Oak galls are structures of modified plant tissue, induced by an ovipositing female oak gall wasp (Hymenoptera: Cynipidae: Cynipini), that provide food and shelter for her progeny. Myriad other wasp species exploit galls, feeding on either the gall wasp larva (parasitoidism), the gall tissue (inquilinism/kleptoparasitism), or other parasites within the gall (hyperparasitism). Though many oak gall-associated wasps are now described, their feeding ecology often remains poorly documented, particularly in the species-rich communities across North America. Wasps in the genus Euceroptres (Hymenoptera: Figitidae) exemplify this problem, long having been assumed to be inquilines based on limited evidence. We used dissections, microcomputed tomography scanning, and DNA barcoding to discover that Euceroptres do not modify the internal composition of their host gall. We also found a Euceroptres larva feeding on gall-inducer larva within an unaltered gall wasp larval chamber. Thus, Euceroptres are parasitoids, not inquilines. While sequencing larval and adult Euceroptres, we also found that the 2 previously described species in eastern North America, Euceroptres whartoni Buffington and Liljeblad, 2008 and Euceroptres primus Ashmead, 1896, did not separate into distinct clades, suggesting they are a single species. Subsequent morphological comparisons support this finding, allowing the establishment of E. whartoni as a syn. nov. of E. primus.

PMID 42729719
Read full article →
PubMedWellcome open research2026-09-13

The genome sequence of an ichneumonid wasp, Ophion crassicornis Brock, 1982 (Hymenoptera: Ichneumonidae).

Broad Gavin R GR, Fletcher Chris C, Holt Stephanie S, Sivess Laura L et al.

We present a genome assembly from an individual female Ophion crassicornis (ichneumonid wasp; Arthropoda; Insecta; Hymenoptera; Ichneumonidae). The genome sequence has a total length of 726.34 megabases. Most of the assembly (98.51%) is scaffolded into 13 chromosomal pseudomolecules. The mitochondrial genome has also been assembled, with a length of 38.03 kilobases. This assembly was generated as part of the Darwin Tree of Life project, which produces genomes for eukaryotic species found in Britain and Ireland.

PMID 42732123
Read full article →
PubMedWellcome open research2026-09-13

The genome sequence of an ichneumonid wasp, Promethes sulcator (Gravenhorst, 1829) (Hymenoptera: Ichneumonidae).

Broad Gavin R GR, Crowley Liam M LM, Januszczak Inez I, Fletcher Chris C et al.

We present a genome assembly from an individual female Promethes sulcator (ichneumonid wasp; Arthropoda; Insecta; Hymenoptera; Ichneumonidae). The genome sequence has a total length of 278.74 megabases. Most of the assembly (99.67%) is scaffolded into 10 chromosomal pseudomolecules. The mitochondrial genome has also been assembled, with a length of 29.43 kilobases. This assembly was generated as part of the Darwin Tree of Life project, which produces genomes for eukaryotic species found in Britain and Ireland.

PMID 42729035
Read full article →
PubMedWellcome open research2026-09-13

The genome sequence of an ichneumonid wasp, Venturia canescens (Gravenhorst, 1829) (Hymenoptera: Ichneumonidae).

Crowley Liam M LM, University of Oxford and Wytham Woods Genome Acquisition Lab, Darwin Tree of Life Barcoding Collective, Wellcome Sanger Institute Tree of Life Management, Samples and Laboratory team et al.

We present a genome assembly from an individual female Venturia canescens (ichneumonid wasp; Arthropoda; Insecta; Hymenoptera; Ichneumonidae). The genome sequence has a total length of 299.96 megabases. Most of the assembly (97.25%) is scaffolded into 11 chromosomal pseudomolecules. The mitochondrial genome has also been assembled, with a length of 27.35 kilobases. Gene annotation of this assembly on Ensembl identified 14 281 protein-coding genes. This assembly was generated as part of the Darwin Tree of Life project, which produces reference genomes for eukaryotic species found in Britain and Ireland.

PMID 42728952
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about SCIT Wasp